Patients suffered pyrogenic reactions before Fresenius Kabi recalled 3 contaminated batches at its 430,000-sq-ft Melrose Park, Ill., biologics plant.
|Articles|July 1, 2014
- BioPharm International-07-01-2014
- Volume 27
- Issue 7
Quantitative Mycoplasma DNA Offers Quality Control
Quantitative Mycoplasma DNA Offers Quality Control
Advertisement
ATCC has expanded its solutions for mycoplasma quality control to include quantitative mycoplasma genomic DNA prepared as Certified Reference Materials. These preparations support its range of quality control products, which include the Universal Mycoplasma Detection Kit and a collection of 10 titered mycoplasma reference strains. ATCC Certified Reference Materials are calibrated to one or more specified properties, making them useful in challenge assays, verifying or comparing test methods, and benchmarking assay performance during assay validation or implementation. Quantitative mycoplasma DNA Certified Reference Materials were isolated from strains most frequently associated with cell culture contamination, and were quantified for genome copy number using digital PCR-based technology.
Articles in this issue
over 12 years ago
Benefits and Risks of Drug Information on Social Mediaover 12 years ago
Health Systems Raise the Bar on Reimbursing New Drugsover 12 years ago
Microbioreactors Increase Productivityover 12 years ago
Moving the Needle on Healthcareover 12 years ago
Analyzing Proteins Using SEC, MALS, and UHPLCover 12 years ago
Brazil's Phytotherapic Drug Market and Regulationover 12 years ago
Industry Seeks Clearer Standards for Track and Traceover 12 years ago
Supplier Audit Program Marks Progressover 12 years ago
Optimizing Human Performance: Part IAdvertisement
Related to this article
NouvSight001 isn't limited to the RPE65-mutation subset current gene therapy treats, potentially reaching more of the 1.5 million with RP worldwide.
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.
Denosumab-adet now covers all 3 Xgeva indications, widening lower-cost treatment access for cancer patients with bone complications.
More than half of patients achieved clear or almost clear hands and feet with lebrikizumab by week 16, and 77% reported satisfaction with clearance.
Updated 36-month data in 15 high-dose patients showed 80% slowing on cUHDRS, while the 48-month cUHDRS result did not reach statistical significance. uniQure attributes the gap to attrition in the external control, and the FDA is reviewing a BLA based on the 36-month data.
Advertisement
Advertisement